2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3776 Impact of portal hypertension on spleen response in MPN patients treated with JAK inhibitors

Marta Davidson, PhD MD, Elliot Smith, MD2, Eshetu Atenafu3, Verna Cheung, BScN, RN MN CON(C)4, Dawn Maze Sr, MD5, Taylor Nye6, Hassan Sibai, MD, Msc, BSc7, Florence Wong, MD8, Vikas Gupta, MD FRCP, FRCPath9
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 University Health Network, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Background: Portal hypertension (PH) may complicate the clinical course of patients with BCR::ABL1-negative myeloproliferative neoplasms (MPN) who require Janus kinase inhibitor (JAKi) therapy; however, the impact of PH on the safety and efficacy of JAKi remains poorly defined; similarly the influence of JAKi therapy on PH is undefined.

Methods: We conducted a retrospective cohort study of patients with MPN or MPN/MDS overlap who underwent esophagogastroduodenoscopy (EGD) in temporal proximity to JAKi initiation and were classified according to the presence or absence of EGD manifestations of PH, including varices and/or portal hypertensive gastropathy. The primary endpoint was achievement of ≥50% palpable spleen length reduction (PSLR) at 24 weeks. Secondary endpoints included other spleen response measures, grade ≥3 adverse events, serial endoscopic PH assessments, and overall survival. Categorical and continuous variables were compared using Fisher’s exact and Wilcoxon rank-sum tests, respectively. Baseline predictors of 24-week spleen response were evaluated using univariate and multivariable logistic regression. Overall survival was analyzed using the Kaplan-Meier method.

Results: The cohort included 99 patients, of whom 46 had EGD-defined PH and 53 did not. Compared with patients without PH, patients with PH were less likely to have fibrotic MPN (39/46 [84.8%] vs 52/53 [98.1%], p=0.023). Among patients with PH, 13/46 (28.3%) had prior splanchnic thrombosis. Most patients received ruxolitinib (92/99, 92.9%). Among 65 evaluable patients, 28 (43.1%) achieved ≥50% PSLR at 24 weeks, with no significant difference between patients with and without PH (11/32 [34.4%] vs 17/33 [51.5%], p=0.21). Median PSLR at a median of 24 weeks (18-30 weeks) was -37.0% overall (-100% to +114.3%) and was similar by PH status (PH: -35.4% [-100% to +114.3%], n=32 vs no PH: -37.0% [-100% to +16.7%], n=33; p=0.79). Among 92 patients evaluable within the first year, rates of ≥50% PSLR (23/41 [56.1%] vs 26/51 [51.0%], p=0.68), best percent PSLR (PH: -50.0% [-100% to +114.3%], n=41 vs no PH: -50.0% [-100% to +5.6%], n=51; p=0.90), and median time to best spleen response (PH: 21.7 weeks [4.0–49.0], n=41 vs no PH: 19.6 weeks [1.9–64.0], n=51; p=0.35) were similar between patients with and without PH. In univariate logistic regression, categorical baseline spleen (OR 0.10, 95% CI 0.03–0.41; p=0.001), continuous palpable spleen length at JAKi initiation (OR 0.91, 95% CI 0.84–0.98; p=0.02), peripheral blood blast percentage (OR 0.64, 95% CI 0.43–0.94; p=0.02), and categorical driver mutation (OR 3.79, 95% CI 1.03–13.95; p=0.045) were associated with achieving ≥50% PSLR at 24 weeks, while JAK2-mutated status showed a trend toward association (OR 3.14, 95% CI 0.97–10.09; p=0.055). PH was not associated with the primary endpoint. In the diagnosis-level model, SMF was associated with lower odds of response compared with PMF, whereas PV and MDS/MPN were not, although the overall diagnosis term was not statistically significant. In multivariable logistic regression including PH status, peripheral blood blast percentage, and baseline spleen category, PH was not significantly associated with the primary endpoint (adjusted OR 0.31, 95% CI 0.09–1.02; p=0.055), whereas peripheral blood blast percentage (adjusted OR 0.66, 95% CI 0.44–0.99; p=0.044) and baseline spleen category (adjusted OR 0.11, 95% CI 0.02–0.50; p=0.004) retained statistical significance. Grade ≥3 hematologic toxicities within 24 weeks occurred in 25/98 (25.5%) evaluable patients and did not differ by PH status (24.4% vs 26.4%, p=1.00). Among 26 patients with PH who underwent serial EGD follow-up, PH findings were stable or improved in 21 (81%), although 21 (85%) received PH-directed therapy before or during JAKi treatment. With a median follow-up of 28 months, overall survival did not differ by PH status. Conclusions: In this EGD-defined PH cohort, JAKi therapy produced clinically meaningful spleen responses and had comparable early hematologic safety in patients with and without PH. Of note, a majority of patients had compensated PH. PH status was not independently associated with significantly inferior 24-week spleen response, although a numerically lower adjusted odds of response warrants further study. These findings support the feasibility of JAKi therapy in carefully selected MPN patients with PH when combined with appropriate endoscopic and hepatology-directed management.

Marta Davidson, PhD MD: No relevant conflicts of interest to declare.